Amgen Inc. (AMGN)

BLA Includes Data From Pivotal Phase 3 Studies of More Than 11,000 Patients

Investors might be finally recognizing the hidden value of the firms' drug research and development.

Let's go to the charts.

Results From a One-Year Study of Efficacy and Safety of Aimovig in Chronic Migraine and Data From a Three-Year Analysis Assessing Safety and Tolerability of Aimovig in Episodic Migraine Will be Presented at the American Headache Society Annual Meeting

$11 Billion is Estimated to be Lost by American Employers Each Year Due to Migraine

The My Migraine Voice Survey Involved More Than 11,000 People Globally, 10 Percent of Which Were From the U.S., and Highlights Urgent Need for Better Care for Benefit of Patients and Society

Study Evaluated Efficacy and Safety of ABP 710 Compared With Infliximab in Patients With Moderate-to-Severe Rheumatoid Arthritis

Data Presented at the 78th Scientific Sessions of the American Diabetes Association

BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy

While the CREATES ACT passed out of committee in the Senate, Senator Orrin Hatch, who helped pave the way for generic drugs in the U.S,,voted against the measure.

The most recent short interest data has been released for the 05/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

KYPROLIS, Lenalidomide and Dexamethasone Extended Median Overall Survival in Relapsed or Refractory Multiple Myeloma Patients to 48 Months

Third Indication in Europe for Prolia for the Treatment of Patients at Increased Risk of Fractures

THOUSAND OAKS, Calif., June 7, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 39 th Annual Global Healthcare Conference at 9:30 a.

Amgen's First Public-Private Partnership with a State Medicaid Agency to Help Improve Patient Health Care Needs Through Data, Science and Information

Stocks are mixed Tuesday but traders continue to snap up tech stocks.

Jim Cramer talks about the stocks and sectors behind the resurgence fueling the Nasdaq's gains.

The Nasdaq hit an all-time high today, and It's Not Just FANG anymore.

Jim Cramer says the market like this economy; he has your game plan for next week.

Less Frequent Once-Weekly KYPROLIS Regimen Also Significantly Increased Overall Response Rates With a Comparable Safety Profile Versus a Twice-Weekly Regimen

For the trade, I'm opting to use the iShares Nasdaq Biotechnology ETF.

Options spreads aren't tradable with some small biotechs, making shares the only way to play.

Here's what you need to know now for Friday, May 18.